arrow_back Back to App

Supporting Research and Treatment for Fungal Diseases, Including Valley Fever

This act aims to accelerate research into fungal diseases, such as Valley Fever, and to develop new treatments and vaccines. Citizens can expect improved diagnostics and more effective treatment methods for these conditions, enhancing their health and safety.
Key points
Increased funding for research on fungal diseases, including Valley Fever, with $20 million annually until 2026.
Establishment of an expert working group to coordinate efforts and identify gaps in fungal disease research.
Expedited approval process for new drugs, diagnostics, and vaccines for Valley Fever by the Food and Drug Administration (FDA).
Creation of a program to support the development of products combating antimicrobial resistance, with a budget of $500 million until 2026, at least 10% of which is allocated to antifungal product development.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_5566
Sponsor: Rep. McCarthy, Kevin [R-CA-23]
Process start date: 2021-10-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

FORWARD Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_5566.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-10-12.

What are the main provisions?

Key points include:

  • Increased funding for research on fungal diseases, including Valley Fever, with $20 million annually until 2026.
  • Establishment of an expert working group to coordinate efforts and identify gaps in fungal disease research.
  • Expedited approval process for new drugs, diagnostics, and vaccines for Valley Fever by the Food and Drug Administration (FDA).
  • Creation of a program to support the development of products combating antimicrobial resistance, with a budget of $500 million until 2026, at least 10% of which is allocated to antifungal product development.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. McCarthy, Kevin [R-CA-23].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health